Help keep your patients on track
Welcome to Nutropin GPS
The Nutropin GPS™ program lets you track your patients' progress from the first SMN submission through the end of therapy. It lets you know where they are, so you can help them stay on track with their treatment.
With Nutropin GPS, you can...
- Track patients, from the first SMN submission through the end of therapy
- Instantly access reports on patient status 24/7, with progress updated daily
- Receive automatic notifications of significant milestones for your patients
You can also speak to your dedicated Case Manager by calling 1-866-NUTROPIN (1-866-688-7674).
INDICATIONSNutropin therapy is indicated for the treatment of pediatric patients who have short stature or growth failure as a result of:
- Growth hormone deficiency (GHD)
- Idiopathic short stature (ISS), defined by height standard deviation score <-2.25, associated with growth rates unlikely to result in normal adult height, in whom other causes of short stature have been excluded
- Turner syndrome
- Chronic kidney disease (CKD) up to the time of renal transplantation
Nutropin therapy is indicated for the replacement of endogenous GH in adults with GH deficiency, either:
- Adult-onset, as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
- Childhood-onset. Patients treated for GH deficiency in childhood who have closed epiphyses should be reevaluated
IMPORTANT SAFETY INFORMATION
- Acute Critical Illness: Somatropin should not be used to treat patients with acute critical illness due to complications following open heart surgery,
abdominal surgery or multiple accidental trauma, or those with acute respiratory failure. A significant increase in mortality has been reported in such cases
- Prader-Willi Syndrome (PWS) in Children: Somatropin should not be used in pediatric patients with PWS who are severely obese, have a history of upper airway
obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death after initiation of somatropin treatment in such patients.
Nutropin AQ is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed PWS.
- Active Malignancy: Somatropin is contraindicated in patients with any evidence of active malignancy. Growth hormone deficiency may be an early sign of a
pituitary tumor or other intracranial tumor; the presence of such a tumor should be excluded before initiation of somatropin treatment
- Diabetic Retinopathy: Somatropin is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy
- Closed Epiphyses: Somatropin should not be used for growth promotion in pediatric patients with closed epiphyses
- Hypersensitivity: Nutropin therapy is contraindicated in patients with a known sensitivity to somatropin or excipients. Localized reactions are the most
common hypersensitivity reactions
WARNINGS AND PRECAUTIONS
- Patients with a history of GHD secondary to an intracranial neoplasm should be monitored routinely while on somatropin therapy for progression or recurrence of the
tumor. Patients on somatropin therapy should be monitored carefully for increased growth, or potential malignant changes, of preexisting nevi. Because children with
certain rare genetic causes of short stature have an increased risk of developing malignancies, these patients should be carefully monitored for development of
neoplasms, if treatment with somatropin is initiated.
- Glucose intolerance and diabetes mellitus
- Intracranial hypertension
- Fluid retention
- Patients with hypopituitarism should have their other hormonal replacement treatments closely monitored during somatropin treatment
- Slipped capital femoral epiphysis in pediatric patients
- Progression of pre-existing scoliosis in pediatric patients
- Otitis media and cardiovascular disorders in patients with Turner syndrome
- Children with growth failure secondary to CKD should be examined periodically for evidence of progression of renal osteodystrophy
- Injection site should be rotated to avoid tissue atrophy. Patients should be informed that local or systemic allergic reactions may occur and that prompt medical
attention should be sought in such cases
- Serum levels of inorganic phosphorus, alkaline phosphatase, parathyroid hormone and IGF-I may increase during somatropin therapy
- Somatropin should be used during pregnancy only if clearly needed and with caution in nursing mothers because it is not known whether somatropin is excreted in
- Clinical studies of somatropin did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger
- Somatropin inhibits 11ß-hydroxysteroid dehydrogenase type 1 (11ßHSD-1) in adipose/hepatic tissue and may significantly impact the metabolism of cortisol and
cortisone. As a consequence, in patients treated with somatropin, previously undiagnosed central (secondary) hypoadrenalism may be unmasked, requiring glucocorticoid
- Careful monitoring is advisable when somatropin is administered in combination with insulin and/or other hypoglycemic agents, other drugs metabolized by CYP450
liver enzymes (eg, hydrocortisone or other corticosteroids, sex steroids, anticonvulsants, cyclosporine), or other hormone replacement therapy
MOST COMMON ADVERSE REACTIONS
- Common adverse reactions reported in adult and pediatric patients taking somatropin include injection site reactions. Additional common adverse reactions in adults
include edema, arthralgia, and carpal tunnel syndrome.
You may report side effects to FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may
also report side effects to Genentech at (888) 835-2555.
Please see accompanying full Prescribing Information for additional Important Safety Information.